US Edition
SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines
- SpliceBio secured $135 million in Series B funding to support the initiation of Phase I/II clinical trials for its lead gene therapy candidate, SB-007, targeting Stargardt disease starting in March.
- The $135 million Series B funding round was spearheaded by first-time backers EQT Life Sciences and Sanofi Ventures, with additional support from Roche Venture Fund and SpliceBio’s existing group of investors, demonstrating strong confidence in the company’s platform.
- SB-007 is a dual AAV gene therapy that delivers a full-length ABCA4 protein by splitting the large gene into two segments linked by-engineered inteins developed with Princeton collaborators.
- An executive from Roche's Venture Fund commended the team for their effective execution and highlighted the platform’s promise in developing a novel category of genetic therapies.
- This financing will support SpliceBio’s clinical development of SB-007 and expansion of its pipeline in ophthalmology, neurology, and other indications.
12 Articles
12 Articles
SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines
Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as all existing investorsProceeds will support clinical development of lead program SB-007 in Stargardt diseaseFunding will also advance a broader pipeline…
SpliceBio Secures $135M Series B to Advance Gene Therapy for Stargardt Disease
SpliceBio announced the closing of a $135 million Series B financing round to support the clinical advancement of SpliceBio’s lead gene therapy candidate, SB-007, for Stargardt disease. There are currently no approved treatments for the disease, which is caused by mutations in the ABCA4 gene. SB-007, based on SpliceBio’s proprietary Protein Splicing platform, is designed to deliver a full-length, functional ABCA4 protein using a dual adeno-assoc…
SpliceBio Raises $135M to Advance Gene Therapy for Stargardt
SpliceBio, a biotechnology company developing gene therapies, announced this Wednesday the closing of a $135 million Series B financing round (€118 million at current exchange rates). The transaction was co-led by EQT Life Sciences and Sanofi Ventures and included participation from Roche Venture Fund and all existing investors: New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys Partners. …
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
